Table 2.

Adverse reactions by the MedRA system organ classification

	Valproate events	Levetiracetam events	Valproate patients (n=257)	Levetiracetam patients (n=258)
Psychiatric disorders	54	109	36 (14%)	66 (26%)
Nervous system disorders	58	46	42 (16%)	37 (14%)
Gastrointestinal disorders	24	20	19 (7%)	15 (6%)
Investigations	31	11	29 (11%)	11 (4%)
General disorders and administration site conditions	20	17	16 (6%)	15 (6%)
Metabolism and nutrition disorders	19	8	19 (7%)	8 (3%)
Skin and subcutaneous tissue disorders	11	6	11 (4%)	5 (2%)
Blood and lymphatic system disorders	1	1	1 (<1%)	1 (<1%)
Eye disorders	1	1	1 (<1%)	1 (<1%)
Respiratory, thoracic, and mediastinal disorders	0	2	0	2 (1%)
Congenital, familial, and genetic disorders	0	1	0	1 (<1%)
Immune system disorders	1	0	1 (<1%)	0
Injury, poisoning, and procedural complications	0	1	0	1 (<1%)